Peer-Reviewed Medical Journal Articles
This page lists articles and letters prepared or contributed to by PHARMAC for publication in peer-reviewed journals.
2011-2012
Usage and equity of access to isotretinoin in New Zealand by deprivation and ethnicity. Moodie P, Jaine R, Arnold J, Metcalfe S, Bignall M and Arroll B. New Zealand Medical Journal, 2011.
Terminations of pregnancy associated with isotretinoin use in New Zealand. Moodie P, Jaine R, Arnold J, Metcalfe S, Bignall M and Arroll B. New Zealand Medical Journal, 2011.
Do pharmaceutical score cards give us the answers we seek?. Moodie P, Metcalfe S, Poynton M. New Zealand Medical Journal, 2011.
2009-2010
New Zealand in fact has no cost-effectiveness threshold. Metcalfe S and Grocott R. International Journal of Environmental Research and Public Health, 2010.
Clarifications on How New Zealand has contained expenditure on drugs. Metcalfe S. E-letter published on British Medical Journal website, 2010. (Comments on Cummings J et al. How New Zealand has contained expenditure on drugs. British Medical Journal, 2010).
Applying Programme Budgeting Marginal Analysis in the health sector: 12 years of experience. Grocott R. Expert Review of Pharmacoeconomics & Outcomes Research, 2009.
Capillary glucose meter accuracy and sources of error in the ambulatory setting. Lunt H, Florkowski C, Bignall M and Budgen C. New Zealand Medical Journal, 2010.
2007-2008
Trastuzumab: possible publication bias (response to Perez & Suman). Laking G, Wells S, Burgess C and Metcalfe S. submitted to The Lancet, 2008. (A complementary letter from Professor Klim McPherson and colleagues was also submitted to The Lancet in 2008.)
Trastuzumab: possible publication bias. Metcalfe S, Burgess C, Laking G, Evans J, Wells S and Crausaz S. The Lancet, 2008. (Content and further details for this article are in the authors' manuscript)
Funding a clinical trial: the perspective of a medicines funder. Alsop P, Metcalfe S and Evans J. Pharmacoeconomics, 2008.
PHARMAC and cardiovascular health in New Zealand. Moodie P. New Zealand Medical Journal, 2008.
Ciproxin HC eardrops application for funding – and response from PHARMAC. Baber WJ, Neeff M and Moodie P. New Zealand Medical Journal, 2008.
Trastuzumab – mechanism of action and use in clinical practice. Metcalfe S and Evans J. submitted to New England Journal of Medicine in 2007.
PHARMAC funding of 9-week concurrent trastuzumab (Herceptin) for HER-2 positive early breast cancer. Metcalfe S, Evans J and Priest G. New Zealand Medical Journal, 2007.
Medicines funding: value for money is nothing new. Brougham M. British Medical Journal, 2007.
PHARMAC responds on Herceptin assumptions and decisions. Metcalfe S and Evans J. New Zealand Medical Journal, 2007.
PHARMAC and statins – correction is needed. Metcalfe S and Moodie P. New Zealand Medical Journal, 2007.
PHARMAC’s updated guidelines for cost-effectiveness analyses, with new discount rate. Grocott R and Metcalfe S. New Zealand Medical Journal, 2007.
Dealing with opportunity cost: a New Zealand perspective on trastuzumab funding. Metcalfe S, Crausaz S, Evans J and Brougham M. E-letter published on British Medical Journal website, 2007.
Balancing the risks and benefits of celecoxib. Caldwell B, Beasley R, Weatherall M and Metcalfe S. American Journal of Medicine, 2007.
2005-2006
Interferon beta, PHARMAC and political directives – PHARMAC clarifies. Metcalfe S and Moodie P. prepared for NZ Medical Journal in 2006.
The impact of a cardiovascular risk awareness campaign on statin prescribing – good news / bad news. Gribben B, Jackson R, Arroll B, Metcalfe S and Goodyear-Smith F. submitted to NZ Medical Journal in 2006.
Commentary on 'The impact of a cardiovascular risk awareness campaign on statin prescribing – good news / bad news'. Metcalfe S and Parore-Katene M. in preparation for NZ Medical Journal during 2006.
The impact of a prescriber awareness campaign on persistent high average daily doses of inhaled steroids in New Zealand primary care. Gribben B, Crampton P, Toop L and Metcalfe S. prepared for NZ Medical Journal in 2006.
PHARMAC and erythropoietin for cancer patients. Grocott R, Metcalfe S and Moodie P. New Zealand Medical Journal, 2006.
PHARMAC and EpiPen for anaphylaxis. Moodie P, Metcalfe S and Dougherty S. New Zealand Medical Journal, 2006.
PHARMAC responds on agents to prevent osteoporotic fractures. Metcalfe S, Wilkinson T and Rasiah D. New Zealand Medical Journal, 2006.
More on PHARMAC and tobacco control in New Zealand. Metcalfe S and Moodie P. New Zealand Medical Journal, 2006.
PHARMAC and statins – getting the best population health gains. Moodie P, Dougherty S and Metcalfe S. New Zealand Medical Journal, 2006.
PHARMAC responds on tolterodine for overactive bladder. Moodie P. New Zealand Medical Journal, 2006.
PHARMAC’s response on clopidogrel. Moodie P and Dougherty S. New Zealand Medical Journal, 2006.
PHARMAC seeks clinical feedback on its cost-utility analysis methodology. Grocott R and Moodie P. New Zealand Medical Journal, 2006.
More from PHARMAC on long-acting insulin analogues: insulin glargine now funded. Moodie P. New Zealand Medical Journal, 2006.
More from PHARMAC on temozolomide: feedback needed. Rasiah D. New Zealand Medical Journal, 2006.
Going against the flow: the impact of PHARMAC not funding COX-2 inhibitors for chronic arthritis. Grocott R and Metcalfe S. New Zealand Medical Journal, 2005.
PHARMAC’s response on temozolomide and funding costly medicines that prolong life shortly. Metcalfe S, Crausaz S, Moodie P and McNee W. New Zealand Medical Journal, 2005.
PHARMAC responds on treatments for pulmonary arterial hypertension. Metcalfe S, Rasiah D and Dougherty S. New Zealand Medical Journal, 2005.
PHARMAC responds on TNF inhibitors for inflammatory arthritis. Metcalfe S, Moodie P, Grocott R and Wilkinson T. New Zealand Medical Journal, 2005.
PHARMAC responds on long-acting inhalers for COPD. Metcalfe S and Dougherty S. New Zealand Medical Journal, 2005.
PHARMAC responds on long-acting insulin analogues. Metcalfe S, Evans J and Moodie P. New Zealand Medical Journal, 2005.
PHARMAC responds on salbutamol. Metcalfe S, Moodie P, Davies A, McNee W and Dougherty S. New Zealand Medical Journal, 2005.
PHARMAC responds to Stewart Mann on dihydropyridine calcium channel antagonists. Davies A, Metcalfe S, Moodie P and McNee W. New Zealand Medical Journal, 2005.
PHARMAC and tobacco control in New Zealand: two licensed funded options are already available. (with responses by Holt et al and the Editor). Metcalfe S, Moodie P and McNee W. New Zealand Medical Journal, 2005.
PHARMAC responds to Richard Milne on discounting health benefits and costs. Metcalfe S, Brougham M, Moodie P and Grocott R. New Zealand Medical Journal, 2005.
PHARMAC welcomes debate. Moodie P, McNee W and Metcalfe S. New Zealand Medical Journal, 2005.
PHARMAC responds to the RMI’s editorial. Moodie P and McNee W. New Zealand Medical Journal, 2005.
PHARMAC’s response to Tim Blackmore on the sole supply of influenza vaccine. McNee W, Moodie P, Schmitt S and Dick A. New Zealand Medical Journal, 2005.
Response to ‘Exceptional circumstances and heart transplantation’ letter. Tomlinson P and Moodie P. New Zealand Medical Journal, 2005.
PHARMAC's response on gemcitabine and transparency. Crausaz S and Metcalfe S. New Zealand Medical Journal, 2005.
2002-2004
Seretide meta-analysis missed important features and overstates any advantages over concurrent LABA/ICS devices. Metcalfe S and Moodie P. Journal of Allergy & Clinical Immunology, 2004.
Patients using diabetes medicines, including the under- and overuse of blood glucose testing. Metcalfe S. in preparation for NZ Medical Journal during 2004.
Specific oral contraceptive use and venous thromboembolism resulting in hospital admission. Heuser P, Tonga K, Hopkins R, Henderson M, Weatherall M, Metcalfe S and Beasley R. New Zealand Medical Journal, 2004.
Statin usage in Australia and New Zealand, and problems with use of DDDs. Metcalfe S and Moodie P. E-letter published on British Medical Journal website, 2004.
Asthma medicines (SABAs, LABAs and ICSs) and hospitalisations by age and by ethnicity over time. Metcalfe S. in preparation for NZ Medical Journal during 2004.
The relationship between trends in long-acting beta-agonist (LABA) use and asthma hospitalisations in New Zealand. Metcalfe S. in preparation for NZ Medical Journal during 2004.
PHARMAC measures savings elsewhere to the health sector. Metcalfe S, Dougherty S, Brougham M and Moodie P. New Zealand Medical Journal, 2003.
More on DTCA and the cost of asthma inhalers. McNee W. New Zealand Medical Journal, 2003.
Direct-to-consumer advertising – yes it can compromise patient health. Metcalfe S, McNee W and Moodie P. New Zealand Medical Journal, 2003.
Response from PHARMAC: difficult choices. Moodie P, Metcalfe S and McNee W. New Zealand Medical Journal, 2003.
Death of pharmacy or safer dispensing?. McNee W. New Zealand Medical Journal, 2003.
More about cardiovascular disease and lipid management in New Zealand. Metcalfe S and Moodie P. New Zealand Medical Journal, 2002.
Old letters, new rules. Metcalfe S. The Lancet, 2002.
Heart Protection Study. Metcalfe S, Dawson S and Milne RJ. The Lancet, 2002.
Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis: celecoxib's relative gastrointestinal safety is overstated. Metcalfe S, Dougherty S and McNee W. British Medical Journal, 2002.
Our advice? Get a budget!. Brougham M, Metcalfe S and McNee W. Healthcare Papers, 2002.
Changes to time trends for inhaled corticosteroid use and costs in New Zealand since April 2002. Metcalfe S. in preparation for NZ Medical Journal during 2003.
1996-2001
Are drugs interchangeable?. McNee W, Moodie P and Metcalfe S. The Lancet, 2000.
PHARMAC at what cost? Moodie P and McNee W. New Zealand Medical Journal, 2000.
Managing pharmaceutical expenditure while increasing access: the Pharmaceutical Management Agency (PHARMAC) experience. Braae R, McNee W and Moore D. Pharmacoeconomics, 1999.
Statins and PHARMAC. McNee W and Smart T. New Zealand Medical Journal, 1998.
PHARMAC and statins. Bennett W and McNee W. New Zealand Medical Journal, 1998.
PHARMAC and flutamide. Bennett W. New Zealand Medical Journal, 1998.
Statins. Bennett W. New Zealand Medical Journal, 1998.
Use of statins In New Zealand: subsidy of statins is limited to particular groups of patients. Bennett W, McNee W, Metcalfe S and Wright JM. British Medical Journal, 1997.
Fluvastatin. Bennett W. New Zealand Medical Journal, 1997.
Need and projected demand for lipid-modifying agents in New Zealand. Metcalfe S. prepared for British Medical Journal in 1996.
